Yahoo Finance • 4 hours ago
The drugmaker is testing its antipsychotic drug Cobenfy for the treatment of psychosis associated with Alzheimer’s disease. Continue Reading... Full story
Yahoo Finance • 6 hours ago
Study Continuation Follows Review of Site Level Data and Recommendation of Data Monitoring Committee BMS Remains Blinded to Study Data PRINCETON, N.J., December 03, 2025--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY, "BMS") today ann... Full story
Yahoo Finance • 11 hours ago
Bristol-Myers Squibb Company (NYSE:BMY) ranks among the Best Low Volatility Investments in December 2025. Cantor Fitzgerald reaffirmed its Neutral rating and $45 price target on Bristol-Myers Squibb Company (NYSE:BMY) on November 24. Recen... Full story
Yahoo Finance • yesterday
[Headquarters of US Food and Drug Administration (FDA)] Grandbrothers * Less than a month after taking the role, Richard Pazdur, the director of the US FDA's Center for Drug Evaluation and Research, has turned in his resignation papers,... Full story
Yahoo Finance • yesterday
A U.S. judge on Monday rejected Bristol Myers Squibb's (BMY [https://seekingalpha.com/symbol/BMY]) bid to dismiss a $6.7 billion lawsuit claiming it cheated shareholders of the former Celgene by delaying federal approval for three dru... Full story
Yahoo Finance • 2 days ago
[Pile of different colourful pills placed next to 20 British pound banknotes.] Oleksandr Siedov An agreement in principle reached between UK and US trade negotiators will have the latter's National Health Service pay 25% higher list price... Full story
Yahoo Finance • 2 days ago
(RTTNews) - Drug maker Bristol Myers Squibb Co. (BMY) announced Monday positive and promising data from the trials in Hematology pipeline, comprising Iberdomide, Golcadomide, BCL6 Degrader, as well as Breyanzi. The company announced the p... Full story
Yahoo Finance • 2 days ago
Iberdomide shows deep and sustained responses in newly diagnosed multiple myeloma First-in-class lymphoma CELMoD™ agent, golcadomide, delivers durable responses in combinations across aggressive and indolent lymphomas First-in-class BCL6... Full story
Yahoo Finance • 3 days ago
Bristol-Myers Squibb Company (NYSE:BMY) is included among the 15 Best Boring Dividend Stocks to Buy.BMY Gains Attention as Bayer Reports FXIa Trial Success Bayer reported positive Phase 3 results for its FXIa inhibitor asundexian, h... Full story
Yahoo Finance • 3 days ago
Key Points Bristol Myers Squibb and Johnson & Johnson have had a tough past few years due to several factors. Both companies are looking to right the ship thanks to new product launches. These healthcare leaders routinely increase their... Full story
Yahoo Finance • 5 days ago
Wondering if Bristol-Myers Squibb is a bargain or overpriced? Let’s dig into what’s behind the numbers so you can decide with confidence. After a rocky start to the year, Bristol-Myers Squibb has staged an impressive rebound, gaining 15.6%... Full story
Yahoo Finance • 6 days ago
We came across a bullish thesis on Bristol-Myers Squibb Company on CompoundingLab’s Substack. In this article, we will summarize the bulls’ thesis on BMY. Bristol-Myers Squibb Company's share was trading at $49 recently. BMY’s trailing and... Full story
Yahoo Finance • 6 days ago
Company Logo The global follicular lymphoma market is witnessing growth due to advancements in targeted therapies and immunotherapies. Follicular lymphoma, an indolent form of non-Hodgkin lymphoma, often presents challenges like relapse a... Full story
Yahoo Finance • 7 days ago
[Pills and money] txking/iStock via Getty Images Individuals covered under Medicare can expect significant savings on the 15 drugs that were selected earlier this year for drug price negotiations under the Inflation Reduction Act starting... Full story
Yahoo Finance • 7 days ago
PRINCETON, N.J., November 26, 2025--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in Citi’s 2025 Global Healthcare Conference on Thursday, December 4, 2025. The company will take part... Full story
Yahoo Finance • 8 days ago
Bristol-Myers Squibb (BMY) shares have seen mixed movement over the past month, with the stock rebounding nearly 9% but still trading below this year’s highs. Investors continue to monitor the company’s performance trends and financials.... Full story
Yahoo Finance • 8 days ago
[United States of America and United Kingdom Flags. 3d Rendering] klenger/iStock via Getty Images * The US and UK governments are said to be close to a deal that would boost prices of prescription drugs in the UK in exchange for avoidin... Full story
Yahoo Finance • 8 days ago
[3D charts graph with gift box, coin, analysis business financial data, online marketing isolated on pink background. business strategy minimal concept, 3d render illustration] warat42/iStock via Getty Images Goldman Sachs’ Tony Pasquarie... Full story
Yahoo Finance • 8 days ago
Dublin, Nov. 25, 2025 (GLOBE NEWSWIRE) -- The "PD-1 Resistant Head and Neck Cancer - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The global market for PD-1 Resistant Head and Neck Can... Full story
Yahoo Finance • 9 days ago
The S&P 500 Index ($SPX) (SPY) on Monday closed up by +1.55%, the Dow Jones Industrials Index ($DOWI) (DIA) closed up by +0.44%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed up by +2.62%. December E-mini S&P futures (ESZ25) rose +1.56%,... Full story